Table 1. Overview of studies according to vaccination schedule in different at-risk populations.

Ref.	Vaccine	Subjects	Age (male/female)	Schedule	Group	Sample size	Adverse events
Yuan2004[31]	RV	Military men a	15–20 y (100/0)	0–7–21 days	T	50	Unclear
	10 ug/dose			0–1–6 months	C	50
Chen2006[29]	RV	Medical students a	15–21 y	0–7–21 days	T	100	Fever and injection
	10 ug/dose		(65/135)	0–1–6 months	C	100	site pain
Yuan2006[30]	RV	Military men a	18–50 y (300/0)	0–7–21 days	T	150	Fever and injection
	10 ug/dose			0–1–6 months	C	150	site pain
Wahl1988[26]	RV	Non-pregnant medical students a	18–40 y (0/53)	0–14–42 days	T	27	Unclear
	10 ug/dose			0–1–6 months	C	26
Ricciardi1990[21]	RV	Health care workers	NR (35/80)	0–1–2–12 months	T	50	Unclear
	20 ug/dose			0–1–6 months	C	65
Hess1992[22]	RV	Medical students	18–73 y	0–1–2–12 months	T	143	Headache, diarrhea
	20 ug/dose	and workers a	(118/166)	0–1–6 months	C	141	and mild fever.
Gizaris1993[19]	RV	Healthy adults	17–22 y	0–1–2–12 months	T	100	local pain, headache,
	20 ug/dose		(100/100)	0–1–6 months	C	100	mild fever
Winter1994[18]	RV	Healthy adults	NR (35/80)	0–1–2–12 months	T	59	Unclear
	20 ug/dose			0–1–6 months	C	56
Marsano1996[13]	RV	Healthy adults a	19–62 y	0–1–2 months	T	113	Unclear
	20 ug/dose		(83/147)	0–1–6 months	C	117
Asli2011[4]	RV	Male Prisoners a	Mean age 34 y	0–7–28–56 days	T	85	Unclear
	20 ug/dose		(169/0)	0–1–6 months	C	84

T = accelerated schedule, C = standard schedule.

^aAll HBsAg, HBsAb, and HBcAb tests were negative. RV = recombinant vaccine; NR = not reported.